following a third resubmission assessed under the orphan equivalent process:
pertuzumab (Perjeta®) is accepted for use within NHSScotland.
Indication under review: In combination with trastuzumab and docetaxel, in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti HER2 therapy or chemotherapy for their metastatic disease.
Addition of pertuzumab to current first-line treatment, trastuzumab plus docetaxel, significantly increased progression-free and overall survival for women with HER2-positive metastatic or locally recurrent unresectable breast cancer.
This SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improves the cost effectiveness of pertuzumab and trastuzumab IV (Herceptin®). This advice is contingent upon the continuing availability of these PAS in NHSScotland or list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- pertuzumab (Perjeta)
- SMC ID:
For use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 14 January 2019